O'Brien S - Search Results

1

HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance.

Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG. Shah N, et al. Leukemia. 2011 Jun;25(6):1036-9. doi: 10.1038/leu.2011.30. Epub 2011 Feb 25. Leukemia. 2011. PMID: 21350559 No abstract available.

2

New drugs in the treatment of chronic lymphocytic leukemia.

Keating MJ, O'Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. Keating MJ, et al. Leukemia. 1992 Nov;6 Suppl 4:140-1. Leukemia. 1992. PMID: 1359203 No abstract available.

3

Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.

Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Robertson LE, et al. Leukemia. 1995 Jun;9(6):943-5. Leukemia. 1995. PMID: 7596181 Clinical Trial.

4

A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.

Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. Robertson LE, et al. Leukemia. 1995 Sep;9(9):1444-9. Leukemia. 1995. PMID: 7658710

5

The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia.

Starostik P, O'Brien S, Chung CY, Haidar M, Manshouri T, Kantarjian H, Freireich E, Keating M, Albitar M. Starostik P, et al. Leuk Res. 1999 Sep;23(9):795-801. doi: 10.1016/s0145-2126(99)00088-0. Leuk Res. 1999. PMID: 10475618 Clinical Trial.

6

Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission.

Oudat R, Keating MJ, Lerner S, O'Brien S, Albitar M. Oudat R, et al. Leukemia. 2002 Apr;16(4):632-5. doi: 10.1038/sj.leu.2402439. Leukemia. 2002. PMID: 11960343

7

Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).

Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M. Faderl S, et al. Leukemia. 2002 Jun;16(6):1045-52. doi: 10.1038/sj.leu.2402540. Leukemia. 2002. PMID: 12040436

8

Immunotherapy of chronic lymphocytic leukemia.

Wierda WG, O'Brien S. Wierda WG, et al. Expert Rev Anticancer Ther. 2001 Jun;1(1):73-83. doi: 10.1586/14737140.1.1.73. Expert Rev Anticancer Ther. 2001. PMID: 12113136 Review.

9

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.

O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. O'Brien SM, et al. Cancer. 2003 Dec 15;98(12):2657-63. doi: 10.1002/cncr.11871. Cancer. 2003. PMID: 14669286 Free article. Clinical Trial.

10

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Giles FJ, et al. Leuk Res. 2005 Jun;29(6):649-52. doi: 10.1016/j.leukres.2004.11.013. Epub 2005 Apr 1. Leuk Res. 2005. PMID: 15863204 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,024 results

Search Page